- Home
- EWTX vs MLNK Comparison
EWTX vs MLNK Comparison
Compare EWTX & MLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- MLNK
- Stock Information
- Founded
- EWTX 2017
- MLNK 1998
- Country
- EWTX United States
- MLNK United States
- Employees
- EWTX N/A
- MLNK N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- MLNK Computer Software: Prepackaged Software
- Sector
- EWTX Health Care
- MLNK Technology
- Exchange
- EWTX Nasdaq
- MLNK Nasdaq
- Market Cap
- EWTX 1.5B
- MLNK 1.3B
- IPO Year
- EWTX 2021
- MLNK 2021
- Fundamental
- Price
- EWTX $13.03
- MLNK $17.12
- Analyst Decision
- EWTX Buy
- MLNK Hold
- Analyst Count
- EWTX 9
- MLNK 7
- Target Price
- EWTX $39.89
- MLNK $20.64
- AVG Volume (30 Days)
- EWTX 892.5K
- MLNK 424.2K
- Earning Date
- EWTX 08-07-2025
- MLNK 08-07-2025
- Dividend Yield
- EWTX N/A
- MLNK N/A
- EPS Growth
- EWTX N/A
- MLNK N/A
- EPS
- EWTX N/A
- MLNK N/A
- Revenue
- EWTX N/A
- MLNK $319,970,000.00
- Revenue This Year
- EWTX N/A
- MLNK $6.24
- Revenue Next Year
- EWTX N/A
- MLNK $5.85
- P/E Ratio
- EWTX N/A
- MLNK N/A
- Revenue Growth
- EWTX N/A
- MLNK 5.15
- 52 Week Low
- EWTX $10.60
- MLNK $15.49
- 52 Week High
- EWTX $38.12
- MLNK $25.33
- Technical
- Relative Strength Index (RSI)
- EWTX 35.20
- MLNK 56.16
- Support Level
- EWTX $12.72
- MLNK $16.09
- Resistance Level
- EWTX $13.37
- MLNK $17.32
- Average True Range (ATR)
- EWTX 0.65
- MLNK 0.57
- MACD
- EWTX -0.16
- MLNK 0.09
- Stochastic Oscillator
- EWTX 24.22
- MLNK 89.17
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.